ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

The War on Drugs is A War on Mental Health: MDMA

Updated on January 2, 2020
Around 8 million adults suffer from PTSD in a given year.
Around 8 million adults suffer from PTSD in a given year. | Source

MDMA, also sometimes incorrectly labeled as “molly” or “ecstasy”, has been modernly perceived as a party drug. It was synthesized in 1912 by German scientists to be used as a pharmaceutical. MDMA eventually had its psychoactive properties researched by the CIA as part of MK-ULTRA; highly classified mind-control research conducted by the U.S. Government in the 1950s. In the 1980s, the rave and recreational culture surrounding MDMA led to its banning by the DEA in 1985 (1).

The effects of MDMA can be both positive and negative. On the plus side, the drug creates a feeling of euphoria and compassion, often leaving the user feeling emotionally healed. Contrarily, long-term use of the substance may cause difficulty with memory and depression, including damage to the serotonin system. “Ecstasy” and “Molly” are usually confused with MDMA, although the former can contain other mixed substances that may lead to a higher chance of unwanted health problems. Research has shown that short-term use is generally safe (2).

Would you believe me if I told you that in 2018, a double-blind study conducted by the British Association for Psychopharmacology resulted in 76 percent of PTSD patients being cured? That means 28 PTSD-diagnosed patients participated in the study, with only about 7 people needing further treatment after a 12-month checkup (3). According to the Multidisciplinary Association for Psychedelic Studies, “at least one in two PTSD patients cannot tolerate or do not respond adequately to existing treatments”. Alternative Medicine is in high demand, and there is substantial evidence pointing to MDMA as a breakthrough solution.

As of August 26th, 2017, MDMA is undergoing phase three of the FDA’s rigorous clinical trial. There are five phases, the third phase consisting of researchers studying the reaction of the drug on the human body. MDMA was granted a “Breakthrough Therapy Designation” by the FDA. The Food and Drug Administration classifies this designation as “a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).” (4). The expected completion date is estimated to be sometime in 2021 and could make the drug available as a prescription.

Last year it is estimated that 30.5 million U.S. citizens used benzodiazepines, the pharmaceutical name for mental relaxation drugs like xanax and valium (5). These drugs combat symptoms of anxiety and depression, and are also highly addictive. According to the National Institute on Drug Abuse, more than 30 percent of overdoses involving opioids also involve benzodiazepines (6). What if there were a safer prescription that could lower the public’s dependence on addictive prescription drugs? What if most patients could still feel cured of mental illness 12 months after their first treatment? The research has shown that even with minimal treatment, a large portion of patients can end up free from PTSD, anxiety, and depression. MDMA may be an important catalyst for the overhaul of U.S. drug policy, as other illegal substances slowly make their way through the FDA’s trial process. There is no easy answer to defeating mental illness, but the way is being paved to replace outdated methods that lead to addiction.

Do you support the legalization of medicinal MDMA?

See results


(1) Editors. “MDMA.”, A&E Television Networks, 31 May 2017,

(2) Lawton, Graham. “Ecstasys Long-Term Effects Revealed.” MAPS, Feb. 2009,'s-long-term-effects-revealed.

(3) Grigsby, Jim, et al. “3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy for Treatment of Chronic Posttraumatic Stress Disorder: A Randomized Phase 2 Controlled Trial - Marcela Ot'alora G, Jim Grigsby, Bruce Poulter, Joseph W Van Derveer, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer, Rick Doblin, 2018.” SAGE Journals, Oct. 2018,

(4) Unknown. “Breakthrough Therapy.” U.S. Food and Drug Administration, FDA, 2018,

(5) National Institute on Drug Abuse, National Institute on Drug Abuse. “Research Suggests Benzodiazepine Use Is High While Use Disorder Rates Are Low.” NIDA, 18 Oct. 2018,

(6) National Institute on Drug Abuse. “Research Suggests Benzodiazepine Use Is High While Use Disorder Rates Are Low.” NIDA, 18 Oct. 2018,


This website uses cookies

As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at:

Show Details
HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
LoginThis is necessary to sign in to the HubPages Service.
Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
AkismetThis is used to detect comment spam. (Privacy Policy)
HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
MavenThis supports the Maven widget and search functionality. (Privacy Policy)
Google AdSenseThis is an ad network. (Privacy Policy)
Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
Index ExchangeThis is an ad network. (Privacy Policy)
SovrnThis is an ad network. (Privacy Policy)
Facebook AdsThis is an ad network. (Privacy Policy)
Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
AppNexusThis is an ad network. (Privacy Policy)
OpenxThis is an ad network. (Privacy Policy)
Rubicon ProjectThis is an ad network. (Privacy Policy)
TripleLiftThis is an ad network. (Privacy Policy)
Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)
ClickscoThis is a data management platform studying reader behavior (Privacy Policy)